becondogrel

Becondogrel is an oral antiplatelet agent and a direct metabolic intermediate of clopidogrel, designed to optimize the activation pathway of thienopyridine therapy. Unlike clopidogrel, which requires a two-step cytochrome P450-mediated oxidative process to become active, becondogrel requires only a single metabolic step to form the active thiol metabolite (H4). This active metabolite irreversibly inhibits the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface, thereby preventing platelet aggregation. By bypassing the initial metabolic step that is heavily dependent on the CYP2C19 enzyme, becondogrel aims to reduce the inter-individual variability in antiplatelet response and mitigate 'clopidogrel resistance' commonly observed in patients with CYP2C19 loss-of-function polymorphisms (intermediate and poor metabolizers). Clinical data indicates that becondogrel at a dose of 4.5 mg achieves bioequivalent active metabolite exposure and antiplatelet effects to a standard 75 mg dose of clopidogrel in normal metabolizers, while providing significantly greater efficacy in poor metabolizers.